INVA

Innoviva, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$18.97

Price (1 Year)

$24.24 $18.97

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %20.7 / %30
Non-compliant assets / Total market cap %44.2 / %30
Non-compliant revenue / Total income %6.9 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.

Website

Analysis (Turkish): INVA Hissesi Caiz mi, Helal mi? Innoviva, Inc. Katılım Analizi